Nykode Therapeutics ASA is a clinical-stage biopharmaceutical company which engages in discovering and developing of novel immunotherapies. The company is headquartered in Oslo, Oslo and currently employs 62 full-time employees. The company went IPO on 2020-01-27. Nykode uses its vaccine technology platform to generate therapeutics in disease indications with unmet medical need. The firm develops next generation vaccines for clinical use, based on a deep understanding of immunological principles. Nykode Therapeutics’ main product candidates are VB10.16 and VB10.NEO. VB10.16 is a therapeutic cancer vaccine against HPV16-related cancers. VB10. NEO is a therapeutic cancer neoantigen vaccine. The firm also has two universal COVID-19 vaccine candidates in development.
Quelle est la performance du prix de l'action NYKODE THERAPEUTICS ASA ?
Le prix actuel de NYKODE THERAPEUTICS ASA est de $0.38, il a diminué de 0% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Nykode Therapeutics AS ?
Nykode Therapeutics AS appartient à l'industrie Biotechnology et le secteur est Health Care
Quel est la capitalisation boursière de Nykode Therapeutics AS ?
La capitalisation boursière actuelle de Nykode Therapeutics AS est de $124.0M
Est-ce que Nykode Therapeutics AS est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 5 analystes ont établi des notations d'analystes pour Nykode Therapeutics AS, y compris 0 achat fort, 0 achat, 3 maintien, 4 vente et 0 vente forte